Alumis

Alumis is a biotechnology and healthcare startup founded in 2021, headquartered in the United States. The company's slogan, "Transforming the lives of patients living with immune-mediated diseases using a precision approach," encapsulates its mission. Alumis aims to revolutionize the treatment of immune-mediated diseases by replacing broad immunosuppression with targeted therapies. The company recognizes the unmet needs of patients living with immune-mediated diseases and is dedicated to pioneering a precision approach. Leveraging powerful data analytics, Alumis aims to select the right target, molecule, indication, patient, and endpoint to produce optimized outcomes for patients. This approach is expected to lead to the development of the next generation of treatments addressing immune dysfunction. Having received a substantial $259.00M Series C investment on March 6, 2024, Alumis has attracted support from a diverse group of investors, including HBM Healthcare Investments, Lilly Asia Ventures, Ally Bridge Group, Cormorant Asset Management, Foresite Capital, Moega Funds, Nextech Invest, Samsara BioCapital, VenBio Partners, and Piper Heartland Healthcare Capital. The company's collaboration with these prominent investors indicates a high level of confidence in its innovative approach. Led by a team of experienced professionals incubated by Foresite Labs, Alumis is committed to developing a pipeline of transformative therapies to effectively address the needs of patients with immune-mediated diseases. This startup presents a compelling investment opportunity in the rapidly evolving biotechnology and healthcare sectors.